The Drug Controller General of India (DCGI) has decided to impose a ban on import of raw material from 10 Chinese drug companies citing non-compliance with manufacturing standards.
The DCGI cancelled the registration of these firms last week, which means that they will nopt be able to export raw material to Indian companies.
"A limited number of Chinese companies supply some of the active pharmaceutical ingredients (APIs) so there can be shortage for that particular lot," an industry executive told the Economic Times.
Some of the ingredients, which were supplied by these firms include clotrimazole, mefenamic acid and sulphadoxine. It is believed that the Chinese firms failed to supply good manufacturing practices (GMP) certificates.